Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01851174 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01851174: Clinical Trial Phase 2 study, sponsored by Western Regional Medical Center.
NCT01851174 is a Phase 2 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01851174, a Phase 2 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
To determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG nab-Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01851174
The ClinicalTrials.gov registry entry for NCT01851174 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT01851174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01851174 about?
NCT01851174 is a clinical study titled "Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer". To determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.
What is the current status of trial NCT01851174?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2013-02. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01851174?
The interventions under investigation include: Gemcitabine (DRUG), nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01851174?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.